Feb 06, 2025
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Jan 27, 2025
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Jan 21, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
Jan 08, 2025
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Jan 06, 2025
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 20, 2024
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY(TM) (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Dec 13, 2024
Neurocrine Biosciences Announces FDA Approval of CRENESSITY(TM) (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Nov 26, 2024
Neurocrine Biosciences to Participate at Investor Conferences in December
Nov 05, 2024
Neurocrine Biosciences to Participate at Investor Conferences in November
Nov 04, 2024
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Nov 04, 2024
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
Sep 30, 2024
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep 10, 2024
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Aug 28, 2024
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
Jul 11, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Jul 01, 2024
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Jun 03, 2024
Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Jun 03, 2024
Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Jun 03, 2024
Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
May 28, 2024
Neurocrine Biosciences Announces CEO Succession Plan